ALEC - Alector, Inc.
| Previous Close | 19.78 |
| Open | 19.75 |
| Bid | 0.00 x 800 |
| Ask | 25.00 x 1300 |
| Day's Range | 18.94 - 21.99 |
| 52 Week Range | 18.00 - 21.99 |
| Volume | 530,142 |
| Avg. Volume | 2,730,500 |
| Market Cap | 1.417B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.07 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNBC Videos•13 days ago
Opening Bell, February 7, 2019
Ringing today's opening bells are Cycle for Survival with Equinox President Scott Rosen at the NYSE and Alector with CEO Arnon Rosenthal at the Nasdaq.
- CNBC Videos•13 days ago
Today's Bell Ringer, February 7, 2019
Today's bell ringers are Cycle for Survival with Equinox President Scott Rosen at the NYSE and Alector with CEO Arnon Rosenthal at the Nasdaq.
- Investor's Business Daily•9 days ago
IPO Market Momentum Gains Speed, Fueled By Biotech Sector
The IPO market is expected to show another uptick in volume this week as six initial public offerings are set to price and raise $882.6 million in proceeds. It follows three IPOs last week.
- American City Business Journals•9 days ago
$70M IPO planned by Santa Clara startup with sonic treatment for cardiovascular disease
ShockWave has raised about $150 million in funding from investors who include Venrock, T. Rowe Price, Sectoral Asset Management, Sofinnova Capital and Fidelity.
- GlobeNewswire•13 days ago
Nasdaq Welcomes Alector, Inc. (Nasdaq: ALEC) to the Nasdaq Stock Market
Alector, Inc. (ALEC), a clinical stage biotechnology company, rang the Nasdaq MarketSite bell in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market. Alector is pioneering immuno-neurology, a novel therapeutic approach to counteract the multiple pathologies that cause degenerative brain disorders by restoring healthy immune function to the brain. Supporting its scientific approach, the Company’s Discovery Platform enables them to advance a broad portfolio of product candidates, validated by human genetics, which they believe will improve the probability of technical success of these product candidates and shorten the development timelines to bring these therapies to patients.
- MarketWatch•13 days ago
Alector's stock opens below IPO price, then swings above it
Shares of newly public biopharmaceutical company Alector Inc. opened just shy of its initial public offering price, before swinging slightly higher in morning trade. The first trade was at $18.70 for about 542,000 shares at 10:39 Eastern, which was 1.6% below the $19 IPO price. The stock was last trading 0.5% above its IPO price. The stock is listed on Nasdaq under the ticker symbol "ALEC." The company has gone public at a time when the iShares Nasdaq Biotechnology ETF has lost 2.1% over the past three months, while the Renaissance IPO ETF has gained 1.2% and the S&P 500 has declined 3.6%.
- MarketWatch•13 days ago
Biopharma company Alector prices IPO at $19, midpoint of price range
Biopharmaceutical company Alector Inc. priced its initial public offering at $19 a share, the midpoint of its $18 to $20 range, according to Nasdaq. The company sold 9.25 million shares to raise $175.8 million. Shares will start trading on Nasdaq later Thursday, under the ticker symbol "ALEC".
- Business Wire•13 days ago
Alector Announces Pricing of Initial Public Offering
Alector, Inc. , a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the pricing of its initial public offering of 9,250,000 shares of common stock to the public at $19.00 per share.
- Benzinga•17 days ago
IPO Outlook For The Week: Biotechs And Blank Checks
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Alector, Inc. (ALEC) will issue 9.25 million shares between $18 and $20 ...
